| Detected | Trial | Change |
|---|---|---|
| 2026-06-10 | NCT07490301 A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With… |
Recruitment opened |
| 2026-06-10 | NCT07490301 A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With… |
Trial sites expanded: 0 -> 9 locations |
| 2026-06-03 | NCT06772623 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… |
Trial sites expanded: 92 -> 96 locations |
| 2026-05-30 | NCT06820463 A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab… |
Trial sites reduced: 50 -> 47 locations |
| 2026-05-28 | NCT06772623 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… |
Trial sites expanded: 85 -> 91 locations |
| 2026-05-28 | NCT06820463 A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab… |
Trial sites expanded: 44 -> 50 locations |
| 2026-05-23 | NCT07005102 A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab… |
Trial sites expanded: 48 -> 53 locations |
| 2026-05-21 | NCT07196644 A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years… |
Enrollment reduced: 125 -> 100 participants |
| 2026-05-21 | NCT07196644 A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years… |
Trial sites expanded: 26 -> 29 locations |
| 2026-05-19 | NCT06772623 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… |
Trial sites expanded: 64 -> 79 locations |
| 2026-05-15 | NCT07023289 A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants… |
Trial sites expanded: 41 -> 44 locations |
| 2026-05-14 | NCT06772623 Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… |
Trial sites reduced: 74 -> 64 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07525206 | A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV… | Colorectal Cancer | Not Yet Recruiting |
| NCT06614192 | A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused… | Metastatic Colorectal Cancer | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT07155187 | A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV)… | Non-Small Cell Lung Cancer | Recruiting |
| NCT07005102 | A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab… | Non-Squamous Non-Small Cell Lung Cancer | Recruiting |
| NCT07490301 | A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With… | Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting |
| Phase 2 | |||
| NCT06628310 | A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV)… | Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma | Recruiting |
| NCT07023289 | A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants… | Colorectal Cancer | Recruiting |
| NCT07196644 | A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years… | Solid Tumors Harboring MET Amplification | Recruiting |
| NCT06820463 | A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab… | Metastatic Colorectal Cancer | Recruiting |
| Phase 1/2 | |||
| NCT06772623 | Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab… | Non Small Cell Lung Carcinoma | Recruiting |
| Phase 1 | |||
| NCT05005403 | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small… | Non-Small Cell Lung Cancer | Recruiting |
| NCT06084481 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With… | Hepatocellular Carcinoma | Active, Not Recruiting |
| NCT06464692 | Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab… | Colorectal Cancer | Active, Not Recruiting |